β2-microglobulin induces depressive- and anxiety-like behaviors in rat

Ping Zhang1,2*, Dan Zeng1,2*, Yi-Li Yi1,2, Yi-Yun Tang2,3, Wei Zou1,2, Xue-Feng Yang4*, Chun-Yan Wang2,5, Xiao-Qing Tang2,3*

1 Department of Neurology, Affiliated Nanhua Hospital, University of South China, Hengyang, Hunan, China, 2 Institute of Neuroscience, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang, Hunan, China, 3 Department of Physiology, Medical College, University of South China, Hengyang, Hunan, China, 4 Department of Gastroenterology, Affiliated Nanhua Hospital, University of South China, Hengyang, Hunan, China, 5 Department of Pathophysiology, Medical College, University of South China, Hengyang, Hunan, China

☯ These authors contributed equally to this work.

* tangxq-usc@qq.com (XQT); yxf9988@126.com (XFY)

Abstract

β2-microglobulin (B2M), the light chain of major histocompatibility complex class I (MHC I) molecules, has been found to impair hippocampal neurogenesis. Based on the crucial role of hippocampal neurogenesis disturbance in the process of depression and anxiety, the aim of the present study is to investigate whether B2M leads to depressive- and anxiety-like behaviors. We found that 6 days after intracerebroventricular injection with B2M (0.3 μg), the immobility times of rats in the tail suspension test and the forced swimming test were increased, the swimming and climbing time in the forced swimming test was decreased, and the latency to feed in the novelty-suppressed feeding test was increased, indicating that B2M induces depressive-like behaviors. In addition, in the elevated plus maze test, B2M-treated rats displayed obvious decline in the number of entries into and the proportion of time spent in the open arm, while the number of total arm entries was no change, which indicated that B2M induces anxiety-like behaviors. Our present findings suggest that target B2M might represent a novel approach for treatment of depression and anxiety.

Introduction

Depression and anxiety are common and serious psychiatric conditions that cause high morbidity, disability and mortality [1, 2]. There is mounting evidence that abnormal adult neurogenesis is closely related to many psychiatric and mental disorders [3–5]. Adult neurogenesis is a complex sequential process that produces new neurons in the brains of adult mammal throughout life span [6]. Adult neurogenesis is impaired in multiple rodent chronic stress models of depression and anxiety [7–11]. Animal studies have shown that decrease in adult neurogenesis could induce depressive-like behavior [12, 13]. In previous studies, adult hippocampal neurogenesis has been definitely impaired in the transgenic animals, which is significantly involved in anxiety-related behaviors [9, 14]. Furthermore, diverse antidepressants boost adult neurogenesis in stressed animals [15–17] and adult neurogenesis is required for...
antidepressant efficacy [11, 18]. As well, recent studies also indicated that neurogenesis played a pivotal role in effective treatment for neurological and psychological disorders [19, 20]. Simultaneously, it appears likely that adult hippocampal neurogenesis has significant effect on human brain functions [21, 22] and induce various brain disorders [23]. Thus, impairment in neurogenesis is a key pathophysiological mechanism of depression and anxiety.

The most major histocompatibility complex class I (MHC I) molecules are known for their role in the vertebrate adaptive immune response [24]. Functional MHC I molecules are composed of a transmembrane heavy chain, a soluble β2-microglobulin (B2M) light chain, and a 9–11 amino acid peptide [25]. B2M plays an important role in the assembly and cell surface expression of functional MHC I molecules [26, 27]. Increased level of soluble B2M has been observed in the cerebral spinal fluid of patients with HIV-associated dementia [28], Parkinson’s diseases [29], and Alzheimer’s disease [30], as well as implicated in cognitive impairments related to chronic hemodialysis [31, 32]. Recently, B2M is deemed to impair hippocampal neurogenesis and synaptic plasticity [33]. Thus, we speculated that B2M may induce depressive- or anxiety-like behaviors. Furthermore, several studies identify that the levels of B2M is increased in the serum or urine of major depressive disorder [34–36]. In addition, B2M also was considered as a housekeeping gene for discriminated asthma with or without depression [37]. Therefore, it is worth to investigating whether B2M leads to depressive- or anxiety-like behaviors.

In the present study, we found that B2M increased the immobility times of in the tail suspension test and the forced swimming test, extended the latency to feed in the novelty-suppressed feeding test, and declined the number of entries into and the proportion of time spent in the open arm in the elevated plus maze test. Our data suggest that B2M play a critical role in the depressive- and anxiety-like behaviors. Regulation of the levels of B2M might reveal a novel therapeutic approach for the treatment of depression and anxiety.

Materials and methods

Animals

Adult male Sprague-Dawley (SD) rats (220–260 g, n = 30), provided by the SJA Lab Animal Center of Changsha (Changsha, Hunan, China), were housed individually in a temperature (22 ± 2˚C) and humidity (55% ± 5%) constant room. Rats were under a 12:12 h light: dark cycle (lights on at 07:00 a.m.) and given free access to standard food and water. The rats were habituated to experimenter and housing conditions for at least 2 weeks before they were tested. In order to avoid information bias, all behavior tests were performed in a blinded manner (observations were removed from analyses). Experiments procedures were carried out according to the National Institute of Health’s Guide for the Care and Use of Laboratory Animals and were approved by the Animal Use and Protection Committee of University of South China. All efforts were made to minimize the amount of animals use as well as their suffering.

Lateral ventricle cannulation

Rats were anesthetized by administration of 60 mg/kg intraperitoneonal sodium pentobarbital (Sigma, St. Louis, MO, USA) before being mounted in stereotaxic apparatus with an incisor-bar and ear-bars; under aseptic conditions, a guide cannula (Rui wo de, Shenzhen, China) was implanted into the right lateral ventricle of rats (1.0 mm posterior to Bregma, 2.0 mm right of the midline, depth of 4 mm below the surface of the skull). The cannulas (5 mm) were permanently attached to the skull with the help of three stainless steel screws and dental cement. After stereotaxic surgery, rats were treated with penicillin (200000 U, intraperitoneally) for two consecutive days and were observed the behavior and wound healing for 7 recovery days in individual feed cage; In order to certify the cannula placement was correct, we
monitored the drinking response after injection of 20 ng AngII (Sigma, St. Louis, MO, USA) into right lateral ventricle. Those consuming more than 5 ml of water in 30 min in response to i.c.v. injection of AngII (a rate of 1 μl/min, 5 min) were confirmed the cannula placement properly and used in the study[38].

**Drugs and treatments**

β₂-microglobulin (B2M) were obtained from Sigma (Sigma, St. Louis, MO, USA). Male SD rats were randomly divided into two different treatment groups: the control group, the B2M-treated group. B2M were dissolved in phosphate-buffered saline (PBS). B2M or vehicles (PBS) were respectively administered into the lateral ventricle in a volume of 3 μl (0.1 μg/μl, a rate of 0.5 μl/min, single dose) and behavior tests were conducted six days after the injection. The experimental schedule has shown in Fig 1.

**Open field test**

An open field test (OFT) was performed to assess the locomotor activity. Locomotor activity in rats was tested in a quiet open field using a locomotion analyzing system (JLBehv-LAR-1; Shanghai Jiliang Software Technology Co. Ltd). The apparatus consisted of a 60 × 60 × 40cm square arena with walls painted black. Briefly, rats were placed in the central of the open-field equipment and allowed to freely explore the area for 5 min. The total distances travelled in the open area was recorded and calculated with a video camera link to computer and regarded as a parameter of motor ability. The apparatus was cleaned between each rat, using 70% ethylalcohol.

**Tail suspension test**

The tail suspension test (TST) in rats was performed as described by our previous reports [39, 40]. In brief, the rats were suspended with a hook by approximately 1 cm from the tip of the tail using adhesive tape (distance from the floor was 50 cm). The experimental period was videotaped and the duration of immobility time was observed for 6 min. Immobility was considered as the animal remaining motionless or making only minor, non-escape-related movements. To prevent visual and acoustic contact between the experimental subjects, the animals were individually placed in the TST apparatus.

**Forced swimming test**

The forced swimming test (FST) was conducted according to the method described by previously report [41]. The rats were placed individually to swim in a plastic cylinder (height: 40

| Adaptation | Lateral ventricle cannulation | B2M (once, i.c.v.) | Behaviour tests |
|------------|-----------------------------|-------------------|-----------------|
| -14d       | -7d                         | 0d                | 6d              |

Fig 1. Schematic diagram of the experimental schedule. B2M, β₂-microglobulin; OFT, open filed test; TST, tail suspension test; FST, forced swimming test; NSFT, novelty suppressed feeding test; EPMT, elevated plus-maze test; i.c.v., intracerebroventricularly.

https://doi.org/10.1371/journal.pone.0198027.g001
cm, diameter: 20 cm) filled with 15 cm of 25 ± 1°C water. The total duration of the stress exposure and behavior were recorded in digital video during the FST. The experiment consisted of two sessions. In a pretest session, each animal was forced to swim individually for 15 min in the water-filled plastic cylinder as an adaptive drill. Twenty-four hours after, the animals were again subjected to 5-min test session of FST. Videos were analyzed by individuals blind to the experimental conditions, and the immobility behavior and escape responses (such as climbing and swimming) was quantified during the test period.

**Novelty-suppressed feeding test**

The novelty-suppressed feeding test (NSFT) was performed according to previous study [42]. The rats were weighed, and food was deprived for 24 h in their cages (water continued to be provided as usually). Approximately 30 minutes of acclimation period, the rats were transferred to a quiet and dark room, placed in a clean novel cage (1 cm of woodchip bedding covered the floor), which a weighed food pellet was putted in the center. Each subject was placed in a corner of the testing arena, and a chronoscope was immediately started. The latency to first feed, defined as sitting their haunches and biting the pellet with forepaws, was recorded. Immediately, the rats were returned to their home cage with a weighed piece of chow for 30 min, the amount of total food intake was measured.

**Elevated plus maze test**

Elevated plus maze test (EPMT) was commonly used to assess anxiety-like behavior as previously described with maze size [43, 44]. In the EPM test for rats, two opposite open arms (50 cm × 10 cm) and two opposite closed arms (50 cm × 10 cm × 40 cm) connected by a central square (10 × 10 cm) make up the apparatus, which are located 50 cm above the floor. The rats were individually placed in the central zone facing one of the open arms, video camera mounted above the maze connected to a computer was used to monitored and scored the explore behavior, during 5-min experimental period. The percentage of open-arm entries (open/total entries × 100) and the proportion of time spent in the open arms (open/total time spent × 100) were calculated for each animal. The more decreased in open arm activity, the more reflected anxiety behavior [45].

**Results**

1. **B2M induces depressive-like behavior in the tail suspension test (TST)**

To explore whether B2M induces a depressive-like effect in rats, the TST was performed. B2M significantly extended the immobility time in TST, indicating that B2M triggers depressive-like behavior in rats (Fig 2).

2. **B2M elicits depressive-like behavior in the forced swimming test (FST)**

The depressive-like effect of B2M was also explored by the FST. As shown in Fig 3, after treatment with B2M, the duration of immobility in the FST was significantly increased (Fig 3A), while the duration of climbing and swimming in the FST were significantly decreased (Fig 3B and 3C). Our data further demonstrated that B2M can elicit depressive-like behavior in rats.

3. **B2M does not affect the locomotor activity in the open field test (OFT)**

To eliminate the possibility of B2M-induced muscular contraction involved in behavior activity, we examined the effects of B2M on motor ability in the OFT. No significant effects were observed for total distance travelled between the B2M-treated and the PBS-injected (control)
Fig 2. Effect of B2M on the behaviors of rats in the tail suspension test. Six days after intracerebroventricular administration of B2M, the rats were tested by TST for 6 min and the immobility time was recorded. Values are represented as mean ± SEM, versus control group.

https://doi.org/10.1371/journal.pone.0198027.g002

Fig 3. Effect of B2M on the behaviors of rats in the forced swimming test. Six days after intracerebroventricular administration of B2M, the rats were evaluated by the FST for 5 min. The immobility (A), climbing (B), and swimming (C) time during the FST was recorded, respectively. All data are represented as mean ± SEM, versus control group.

https://doi.org/10.1371/journal.pone.0198027.g003
group (Fig 4), indicating that behavior changes in the TST and FST were not responsible for altering the nonspecific motoric.

4. B2M exerts depressive-like effect in the novelty-suppressed feeding test (NSFT)

To further test whether B2M exerts a depressive-like effect in rats, we also carried out the NSFT. Compared with control group, the time of latency to feed in the B2M-treated group in novel cage was significantly increased, while, there was no significant difference in latency to feed in home cage (Fig 5A). To exclude the possibility that B2M-induced normal appetite and feed intake ability influenced experiment results, we also monitored the food consumption in novel and home cage for 30 min, respectively. As shown in Fig 5B, there was no significant difference on food consumption in 30 min between the B2M-treated group and the PBS-injected group, whether in novel cage or home cage. The aforementioned results confirm that B2M can exert depressive-like behavior in rats.

5. B2M produces anxiety-like behavior in the elevated plus maze test (EPMT)

To verify the possibility that B2M produces an anxiety-like effect in rats, we assessed the anxiety level of the rats with the EPMT. B2M-exposed rats showed the anxiety-like behavior defined by decreases in the percentage of open arm entries (Fig 6A) and the time spent in the open arm (Fig 6B), with no significant alter in total arm entries (Fig 6C), suggesting that B2M elicits an anxiety-like effect in rats.
Fig 5. Effect of B2M on the behaviors of rats in the novelty-suppressed feeding test. Six days after intracerebroventricular administration of B2M, the rats were assessed by the NSF test. Both latency to feed (A) and feed in 30 min (B) were recorded in the novel and home cage, respectively. Values are expressed as mean ± SEM, versus control group.

https://doi.org/10.1371/journal.pone.0198027.g005

Fig 6. Effect of B2M on the behaviors of rats in the elevated plus maze test. Six days after intracerebroventricular administration of B2M, the rats were tested by the EPM for 5 min. The percentage of open-arm entries (A), the proportion of time spent in the open arms (B) and the number of total arm entries (C) were recorded for each animal. Values are expressed as mean ± SEM, versus control group.

https://doi.org/10.1371/journal.pone.0198027.g006
Discussion
Depression and anxiety are simultaneously experienced [1, 46] and the underlying mechanism remains uncertain, the neurogenic theory might contribute to their pathogenesis [20, 47, 48]. B2M, a pro-aging factor, is known for its toxicity to adult hippocampal neurogenesis [33]. Depression and anxiety disorders tightly associate with adult hippocampal neurogenesis [47, 49]. In the present study, we investigated whether B2M causes depressive- and anxiety-like behaviors. We found that B2M induces depressive-like behaviors in the rats of TST, FST, NSFT and that B2M exerts anxiety-like effect in the rats of EMPT. Our results establish the toxicity of B2M in depression and anxiety disorders.

Accumulating evidence suggests that B2M has closely related to neuropsychiatric disorders. The expression of B2M is significant increase in schizophrenia patients. The mechanism may involve in the impairment of dendritic cell antigen presentation and the imbalance of Th cell differentiation, inducing the cell immune response [50]. In addition, increased level of soluble B2M has been observed in the cerebral spinal fluid of patients with HIV-associated dementia [28], Parkinson’s diseases [29] and Alzheimer’s disease [30]. Therefore, this led us to guess how about the relationship between B2M and depression and anxiety? It has been known that B2M impairs neurogenesis and has related to clinical depression [33, 34]. Furthermore, disturbance of hippocampal neurogenesis is an important pathophysiological mechanism of depression and anxiety. Hence, we investigated whether B2M directly induces depressive- and anxiety-like behaviors in rats.

In this study, administration of B2M results in a conspicuous increase in immobility time in TST of rats, a profound increase in immobility time and a decrease in duration of climbing and swimming in FST, suggesting that B2M produces depressive-like behavior in rats. In addition, treatment with B2M increased the time of latency to feed in novel cage, did not change the food consumption in novel or home cage during the 30 min test session in NSFT, implying that the depressive-like effect of B2M in NSFT was not through affecting normal appetite and feed intake ability. Taken together, our results confirm that B2M can exert depressive-like behaviors in rats.

To eliminate the possibility that B2M induces depressive-like behaviors in rats by influencing muscular contraction, motor ability of rats was evaluated. B2M treatment demonstrated no significant effects on the total distance in open filed test, as compared with control group. The results suggest that the depressive-like effects of B2M in TST, FST, and NSFT are not due to influencing nonspecific motoric.

It is usually identified that depression and anxiety are associated with each other at the same time [1, 46, 48]. On the basis of these researches, it is logical to further hypothesize that B2M may contribute to anxiety-like behaviors in rats. In fact, our results show that administration of B2M for a signal dose obviously decrease both the number of entries into and the proportion of time spent in the open arms of the EPMT, a major confounding factor in this test is the effect of basal locomotor activity, which can be deduced from the number of total entries. As expect, B2M had no effect on the total arm entries. Connectively, our results suggest that B2M dose exert an anxiety-like effect in rats.

Brain-derived neurotrophic factor (BDNF) promotes the regeneration, proliferation and differentiation of hippocampal neurons, and promotes the maturation of newborn neurons [51]. Evidence suggests that, the levels of BDNF were decreased in the models of depression and anxiety, exogenous giving BDNF could ameliorate the depressive- and anxiety-like behaviors, and knockout the expression of BDNF could induce depressive- and anxiety-like behaviors in animals. In addition, BDNF is essential for antidepressant and anxiolytic efficacy[52]. In brief, BDNF has potential role in pathophysiology of many psychiatric diseases or serves as
a therapeutic target for treatment of these diseases. It is worthy to speculate whether B2M impairs neurogenesis and induces depressive- and anxiety-like behaviors are relate to inhibiting the expression of BDNF and exogenous giving BDNF can reverse the toxicity of B2M in neuroprotective depression and anxiety disease? Whether other neuroprotective agents can block these courses?

In conclusion, our study provides evidence that B2M induces depression-like behaviors in the TST, FST, and NSF tests of rats. In addition, this study has also demonstrated that B2M produces anxiety-like behaviors in the EPM tests. However, it should be noted that this study has examined only in behaviors tests, the underlying pathophysiological mechanisms that account for this relationship have yet to be elucidated. Findings from this study will provide new direction to uncover the pathogenesis of depression and anxiety diseases. In near future, we will explore specific mechanisms and effective neuroprotectant for blocking the toxicity effects of B2M on depression and anxiety disorders.

Statistical analyses
All experiments were repeated at least three independent trials. All data are expressed as mean ± standard error of the mean (SEM) and analyses were performed using SPSS 20.0 statistical software (IBM SPSS, Chicago, IL, USA). Statistical significance was determined using one-way analysis of variance (ANOVA) tests followed by Least-significant difference (LSD) test for evaluated within different group, and using Student’s t-test to determined Statistical differences between two sets of groups. Significant main effects (P < 0.05) were further analyzed using post hoc tests.

Acknowledgments
This study was supported by Natural Science Foundation of China (81471310, 81771178), the Major Research Topics of the Health and Family Planning Commission of Hunan province (A2017020), and the Key Projects of the Education Department of Hunan province (17A187). We thank Dr. Xiangping Chu for his critical reading.

Author Contributions
Conceptualization: Ping Zhang, Dan Zeng, Xue-Feng Yang, Xiao-Qing Tang.
Data curation: Dan Zeng, Yi-Li Yi, Yi-Yun Tang.
Formal analysis: Ping Zhang, Dan Zeng, Wei Zou, Chun-Yan Wang.
Funding acquisition: Ping Zhang, Wei Zou.
Investigation: Ping Zhang, Dan Zeng, Xiao-Qing Tang.
Methodology: Dan Zeng, Yi-Li Yi, Xue-Feng Yang.
Project administration: Xue-Feng Yang, Xiao-Qing Tang.
Resources: Ping Zhang, Dan Zeng, Xue-Feng Yang, Xiao-Qing Tang.
Supervision: Xiao-Qing Tang.
Validation: Ping Zhang, Dan Zeng, Xue-Feng Yang, Xiao-Qing Tang.
Writing – original draft: Ping Zhang, Dan Zeng.
Writing – review & editing: Dan Zeng, Xue-Feng Yang, Xiao-Qing Tang.
References

1. Verhoof E, Maurice-Stam H, Heymans H, Grootenhuis M. Health-related quality of life, anxiety and depression in young adults with disability benefits due to childhood-onset somatic conditions. Child Adolesc Psychiatry Ment Health. 2013; 7(12):1–9. https://doi.org/10.1186/1753-2000-7-12 PMID: 23587404; PubMed Central PMCID: PMC3636007.

2. Consortium C. Sparse whole-genome sequencing identifies two loci for major depressive disorder. Nature. 2015; 523(7562):588–91. Epub 2015/07/16. https://doi.org/10.1038/nature14659 PMID: 26176920; PubMed Central PMCID: PMC4522619.

3. Schoenfeld TJ, Cameron HA. Adult neurogenesis and mental illness. Neuropsychopharmacology. 2015; 40(1):113–28. Epub 2014/09/03. https://doi.org/10.1038/npp.2014.230 PMID: 25178407; PubMed Central PMCID: PMC4262910.

4. Kemppainen G, Krebs J, Fabela K. The contribution of failing adult hippocampal neurogenesis to psychiatric disorders. Curr Opin Psychiatry. 2008; 21(3):290–95. https://doi.org/10.1097/YCO.0b013e3282fadd75 PMID: 18382230.

5. Kang E, Wen Z, Song H, Christian KM, Ming GL. Adult Neurogenesis and Psychiatric Disorders. Cold Spring Harb Perspect Biol. 2016; 8(9):1–27. Epub 2016/01/24. https://doi.org/10.1101/cshperspect.a019026 PMID: 26801682.

6. Ming GL, Song H. Adult neurogenesis in the mammalian brain: significant answers and significant questions. Neuron. 2011; 70(4):687–702. Epub 2011/05/26. https://doi.org/10.1016/j.neuron.2011.05.001 PMID: 21609825; PubMed Central PMCID: PMC3106107.

7. Van Bokhoven P, Oomen CA, Hoogendijk WJ, Smit AB, Lucassen PJ, Spijker S. Reduction in hippocampal neurogenesis after social defeat is long-lasting and responsive to late antidepressant treatment. Eur J Neurosci. 2011; 33(10):1833–40. Epub 2011/04/14. https://doi.org/10.1111/j.1460-9568.2011.07668.x PMID: 21488984.

8. Tang MM, Lin WJ, Pan YQ, Guan XT, Li YC. Hippocampal neurogenesis dysfunction linked to depressive-like behaviors in a neuroinflammation induced model of depression. Physiol Behav. 2016; 161:166–73. Epub 2016/04/19. https://doi.org/10.1016/j.physbeh.2016.04.034 PMID: 27106565.

9. Revest JM, Dupret D, Koehl M, Funk-Reiter C, Grosjean N, Piazza PV, et al. Adult hippocampal neurogenesis is involved in anxiety-related behaviors. Mol Psychiatry. 2009; 14(10):959–67. Epub 2009/03/03. https://doi.org/10.1038/mp.2009.15 PMID: 19255582.

10. Yun S, Donovan MH, Ross MN, Richardson DR, Reister F, Farnbauc h LA, et al. Stress-Induced Anxiety- and Depressive-Like Phenotype Associated with Transient Reduction in Neurogenesis in Adult Nestin-CreERT2/Diphtheria Toxin Fragment A Transgenic Mice. PLoS One. 2016; 11(1):e0147256. Epub 2016/01/23. https://doi.org/10.1371/journal.pone.0147256 PMID: 26795203; PubMed Central PMCID: PMC4721672.

11. Perera TD, Dwork AJ, Keegam KA, Thirumangalakudi L, Lipira CM. Necessity of Hippocampal Neurogenesis for the Therapeutic Action of Antidepressants in Adult Nonhuman Primates. PLoS One. 2011; 6(4):e17600. Epub 2011/04/15. https://doi.org/10.1371/journal.pone.0017600 PMID: 21525974; PubMed Central PMCID: PMC3078107.

12. Taliaz D, Stall N, Dar DE, Zangen A. Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviors associated with depression and reduces neurogenesis. Mol Psychiatry. 2010; 15(1):80–92. Epub 2009/07/21. https://doi.org/10.1038/mp.2009.67 PMID: 19621014; PubMed Central PMCID: PMC2834321.

13. Snyder JS, Soumier A, Brewer M, Pickel J, Cameron HA. Adult hippocampal neurogenesis buffers stress responses and depressive behaviour. Nature. 2011; 476(7361):458–61. Epub 2011/08/05. https://doi.org/10.1038/nature10287 PMID: 21814201; PubMed Central PMCID: PMC3162077.

14. Fuss J, Ben Abdallah NM, Hensley FW, Weber KJ, Hellweg R, Gass P. Deletion of Running-Induced Hippocampal Neurogenesis by Irradiation Prevents Development of an Anxious Phenotype in Mice. PLoS One. 2015; 5(9):12769–83. Epub 2015/09/16. https://doi.org/10.1371/journal.pone.012769.g001 PMID: 20892275; PubMed Central PMCID: PMC4240841.

15. Lucassen PJ, Meerlo P, Naylor AS, van Dam AM, Dayer AG, Fuchs E, et al. Regulation of adult neurogenesis by stress, sleep disruption, exercise and inflammation: Implications for depression and antidepressant action. Eur Neuropsychopharmacol. 2010; 20(1):1–17. Epub 2009/08/15. https://doi.org/10.1016/j.eunuro.2009.08.003 PMID: 19748235.

16. Fitzsimons CP, Van Hooijdonk LW, Schouten M, Zalachor I, Brinks V, Zheng T, et al. Knockdown of the glucocorticoid receptor alters functional integration of newborn neurons in the adult hippocampus and impairs fear-motivated behavior. Mol Psychiatry. 2013; 18(9):993–1005. Epub 2012/08/28. https://doi.org/10.1038/mp.2012.123 PMID: 22925833.
17. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic Antidepressant Treatment Increases Neurogenesis in Adult Rat Hippocampus. J Neurosci. 2000; 20(24):9104–10. Epub 2000/12/15. PMID: 11124987.

18. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003; 301(5634):805–9. Epub 2003/08/08. https://doi.org/10.1126/science.1083328 PMID: 12907793.

19. David DJ, Samuels BA, Rainer Q, Wang JW, Marsteller D, Mendez I, et al. Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron. 2009; 62(4):479–93. Epub 2009/05/28. https://doi.org/10.1016/j.neuron.2009.04.017 PMID: 19477151; PubMed Central PMCID: PMC2759281.

20. Petrik D, Lagace DC, Eisch AJ. The neurogenesis hypothesis of affective and anxiety disorders: are we mistaking the scaffolding for the building? Neuropharmacology. 2012; 62(1):21–34. Epub 2011/09/29. https://doi.org/10.1016/j.neuropharm.2011.09.003 PMID: 21945290; PubMed Central PMCID: PMC3698048.

21. Spalding KL, Bergmann O, Alkass K, Bernard S, Salehpour M, Huttner HB, et al. Dynamics of hippocampal neurogenesis in adult humans. Cell. 2013; 153(6):1219–27. Epub 2013/06/06. https://doi.org/10.1016/j.cell.2013.05.002 PMID: 23746839; PubMed Central PMCID: PMC4394608.

22. Christian KM, Song H, Ming GL. Functions and dysfunctions of adult hippocampal neurogenesis. Annu Rev Neurosci. 2014; 37:243–62. Epub 2014/07/03. https://doi.org/10.1146/annurev-neuro-071013-014134 PMID: 24905596; PubMed Central PMCID: PMC5531058.

23. Neefjes JJ, Momburg F. Cell biology of antigen presentation. Curr Opin Immunol. 1993; 5:27–34. PMID: 7680870.

24. Van Kaer L, Ashton-Rickardt P, Ploegh H, Tonegawa S. TAP1 Mutant Mice Are Deficient in Antigen Presentation, Surface Class I Molecules, and CD4-8+ T Cells. Cell. 1992; 71:1205–14. Epub 1992/12/24. PMID: 1473153.

25. Zijlstra M, Bix M, Simister NE. Beta 2 microglobulin deficient mice lack CD4-8+ cytolytic T cells. Nature. 1990; 344:742–6. Epub 1990/04/19. https://doi.org/10.1038/344742a0 PMID: 2139497.

26. Murray AM. Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden. Adv Chronic Kidney Dis. 2008; 15(2):123–32. Epub 2008/03/13. https://doi.org/10.1053/j.ackd.2008.01.010 PMID: 18334236; PubMed Central PMCID: PMC2504691.

27. Smith LK, He Y, Park JS, Bieri G, Snethlage CE, Lin K, et al. β2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis. Nat Med. 2015; 21(8):932–7. Epub 2015/06/06. https://doi.org/10.1038/nm.3898 PMID: 26147761; PubMed Central PMCID: PMC4529371.

28. Lamsers F, Otten-Rijnders P, Ploegh H, Tonegawa S. TAP1 Mutant Mice Are Deficient in Antigen Presentation, Surface Class I Molecules, and CD4-8+ T Cells. Cell. 1992; 71:1205–14. Epub 1992/12/24. PMID: 1473153.

29. Jiang S, Sokal I, Peskind ER, Quinn JF, Jankovic J, Kenney C, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008; 129(4):526–9. Epub 2008/03/18. https://doi.org/10.1309/W0IYB8B08EMEH12L PMID: 18343778; PubMed Central PMCID: PMC2688655.

30. Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, Burkhard P, et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer’s disease. Proteomics. 2003; 3(8):1486–94. Epub 2003/08/19. https://doi.org/10.1021/pr020022c PMID: 12923774.

31. Murray AM. Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden. Adv Chronic Kidney Dis. 2008; 15(2):123–32. Epub 2008/03/13. https://doi.org/10.1053/j.ackd.2008.01.010 PMID: 18334236; PubMed Central PMCID: PMC2504691.

32. Smith LK, He Y, Park JS, Bieri G, Snethlage CE, Lin K, et al. β2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis. Nat Med. 2015; 21(8):932–7. Epub 2015/06/06. https://doi.org/10.1038/nm.3898 PMID: 26147761; PubMed Central PMCID: PMC4529371.

33. Lamsers F, Otten-Rijnders P, Ploegh H, Tonegawa S. TAP1 Mutant Mice Are Deficient in Antigen Presentation, Surface Class I Molecules, and CD4-8+ T Cells. Cell. 1992; 71:1205–14. Epub 1992/12/24. PMID: 1473153.

34. Jiang S, Sokal I, Peskind ER, Quinn JF, Jankovic J, Kenney C, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008; 129(4):526–9. Epub 2008/03/18. https://doi.org/10.1309/W0IYB8B08EMEH12L PMID: 18343778; PubMed Central PMCID: PMC2688655.

35. Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, Burkhard P, et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer’s disease. Proteomics. 2003; 3(8):1486–94. Epub 2003/08/19. https://doi.org/10.1021/pr020022c PMID: 12923774.

36. Murray AM. Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden. Adv Chronic Kidney Dis. 2008; 15(2):123–32. Epub 2008/03/13. https://doi.org/10.1053/j.ackd.2008.01.010 PMID: 18334236; PubMed Central PMCID: PMC2504691.

37. Smith LK, He Y, Park JS, Bieri G, Snethlage CE, Lin K, et al. β2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis. Nat Med. 2015; 21(8):932–7. Epub 2015/06/06. https://doi.org/10.1038/nm.3898 PMID: 26147761; PubMed Central PMCID: PMC4529371.
37. Wang T, Liang ZA, Sandford AJ, Xiong XY, Yang YY, Ji YL, et al. Selection of suitable housekeeping genes for real-time quantitative PCR in CD4(+) lymphocytes from asthmatics with or without depression. PLoS One. 2012; 7(10):e48367. Epub 2012/10/24. https://doi.org/10.1371/journal.pone.0048367 PMID: 23110234; PubMed Central PMCID: PMC3480507.

38. Choi Y, Li C, Page K, Westby A, Dellafera M, Lin J, et al. Melanocortin receptors mediate leptin effects on feeding and body weight but not adipose apoptosis. Physiology & Behavior. 2003; 79(4–5):795–801. https://doi.org/10.1016/s0031-9384(03)00205-1 PMID: 12954425.

39. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl). 1985; 85(3):367–70. PMID: 3923523.

40. Cryan JF, Mombereau C, Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev. 2005; 29(4–5):571–625. Epub 2005/05/14. https://doi.org/10.1016/j.neubiorev.2005.03.009 PMID: 15890404.

41. Cryan JF, Valentino RJ, Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev. 2005; 29(4–5):547–69. Epub 2005/05/17. https://doi.org/10.1016/j.neubiorev.2005.03.008 PMID: 15893822.

42. Bodnoff SR, Suranyi-Cadotte B, Atken DH, Quirion R, Meaney M. The effects of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacology (Berl). 1988; 93(3):298–302. PMID: 3137614.

43. Hogg S. A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol Biochem Behav. 1996; 54(1):21–30. PMID: 8728355.

44. Haller J, Alici M. Current animal models of anxiety, anxiety disorders, and anxiolytic drugs. Curr Opin Psychiatry. 2012; 25(1):59–64. Epub 2011/12/14. https://doi.org/10.1097/YCO.0b013e32834de34f PMID: 22156938.

45. Pinheiro SH, Zangrossi H Jr, Del-Ben CM, Graeff FG. Elevated mazes as animal models of anxiety: effects of serotonergic agents. An Acad Bras Cienc. 2007; 79(1):71–85. PMID: 17401477.

46. Lammers F, Van Oppen P, Comjik HC, Smit JH, Spinnoven P, Van Balkom AJ, et al. Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands Study of Depression and Anxiety (NESDA). J Clin Psychiatry. 2011; 72(3):341–8. Epub 2011/01/25. https://doi.org/10.4088/JCP.10m06176blu PMID: 21294994.

47. Miller BR, Hen R. The current state of the neurogenic theory of depression and anxiety. Curr Opin Neurol. 2015; 30:51–8. Epub 2014/09/18. https://doi.org/10.1016/j.coon.2014.08.012 PMID: 25240202; PubMed Central PMCID: PMC4293252.

48. Kastenschmidt EK, Kennedy GJ. Depression and Anxiety in Late Life: Diagnostic Insights and Therapeutic Options. Mt Sinai J Med. 2011; 78(4):527–45. https://doi.org/10.1002/msj.20266 PMID: 21748742.

49. Siopi E, Denizet M, Gabelle MC, de Chaumont F, Olivo-Marin JC, Guilloux JP, et al. Anxiety- and Depression-Like States Lead to Pronounced Olfactory Deficits and Impaired Adult Neurogenesis in Mice. J Neurosci. 2016; 36(2):518–31. Epub 2016/01/13. https://doi.org/10.1523/JNEUROSCI.2817-15.2016 PMID: 26758842.

50. Xie J, Wang Y, Freeman ME, Barlogie B, Yi Q. β2 microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells. Blood. 2003; 101(10):4005–12. https://doi.org/10.1182/blood-2002-11-3368 PMID: 12531797.

51. Scharfman H, Goodman J, Macleod A, Phani S, Antonelli C, Croll S. Increased neurogenesis and the ectopic granule cells after intrahippocampal BDNF infusion in adult rats. Exp Neurol. 2005; 192(2):348–56. https://doi.org/10.1016/j.expneurol.2004.11.016 PMID: 15755552.

52. Aturty AE, Monteggia LM. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev. 2012; 64(2):238–58. https://doi.org/10.1124/pr.111.005108 PMID: 22407616; PubMed Central PMCID: PMC3310485.